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ABSTRACT 
Background: In Malaysia, it has been reported that drug-induced renal injury is one of the top 
10 types of adverse drug reactions (ADRs) reported in Malaysia. The incidence has increased 
throughout the year sand a closer view needs to be taken. To date, studies that investigate the 
nephrotoxicity based on the spontaneous ADR reporting database in Malaysia are very limited. 
Objectives: To analyse the data on spontaneous ADR reports related to drug-induced renal 
injuries and urinary system disorders in Malaysia from 2010 to 2014. In addition, the aims of this 
study also to describe the pattern of drug-induced renal injury reported in Malaysia. This study 
also aimed to determine the predisposing factors that lead to drug-induced renal injury. 
Methods: This is a retrospective study where the data was collected at Pharmacovigilance 
Section, Centre of Post Registration Product, National Pharmaceutical Control Bureau (NPCB). 
A total of 2093 ADR reports from 2010 to 2014 related to the renal disorders were extracted 
from the Quest 2 database, regardless of the seriousness. Reports were classified according to the 
World Health Organisation (WHO) criteria for causality assessment and the types of renal injury 
were determined according to system organ class (SOC) of urinary system disorders. 
Results: From the results, it was found that 1.11 drugs were recorded per report. 52% percent of 
the patients with the studied ADRs were women and almost 49.5% of them were Malay. Patients 
between 46 to 60 years old were found to be highest group of patients reported with drug-
induced renal injuries. It was found that there is no association between gender (P = 0.181), race 
(P = 0.269) and age groups (P = 0.563) and the extent of severity. 85.7% of the reports were 
classified as possible. Pearson chi square test showed that there is a strong association between 
concomitant drug groups and the extent of severity (P < 0.001). Most of cases were reported with 
sub-acute reaction and it was found that there is a strong association between onsets of time 
category and the extent of severity (P = < 0.001) where the latent onset of time has a higher 
occurrence of severe adverse reactions. Out of 1904 cases, face oedema was found to be at the 
top of the list with 60.8% of the reported cases. Diclofenac was found to be the most reported 
drug causing renal injuries. From the statistical analysis, it was found that the only variable 
which is dosage shows a significant association with the increase in the severity of reaction 
caused by diclofenac. 
Conclusion: In conclusion, this study has pointed out diclofenac as the most common drug that 
causes reported renal injuries besides demonstrating the trend of renal injuries due to the use of 
diclofenac. Although diclofenac can be considered as safe and effective therapeutic NSAIDs for 
the management of a variety acute and chronic condition, it has to be used with justifiable 
caution. Healthcare professionals should be aware of the risk for diclofenac associated renal 
injuries and need to screen patients appropriately for impairment risk factors before commencing 
diclofenac therapy. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background of the Study 
In the 1960s, the thalidomide tragedy has opened the eyes of many healthcare 
stakeholders and became the catalyst to the beginnings of the scrupulous drug approval and 
monitoring systems in place at the United States Food and Drug Administration (FDA) today. 
This tragedy and other additional incidents such as adverse reactions towards a high intake of 
estrogen oral contraceptive pills at that time became one of the major reasons for the increasingly 
stringent requirements to document drug safety development and the establishment of 
spontaneous adverse drug reactions reporting system (L Aagaard & Hansen, 2009; Fintel, 
Samaras, & Carias, 2009). Year by year, the increased number of incidences or occurrences of 
unanticipated, serious and alarming adverse drug reactions (hereafter ADRs) has fascinated and 
drawn healthcare professionals and public attention. The spike in these cases has resulted in 
suspicion on the effectiveness and quality of drug surveillance systems. In his article, Horton 
(2004) discusses on a recent example of an ADR case that describes the scandal of 
cyclooxygenase-2 (COX-2) inhibitors which has resulted in the withdrawal of rofecoxib (Vioxx 
®) from the United States (US) market in 2004 due to unexpected emergence of cardiovascular 
events (related to the drug). The case had really taken the world by surprise and grabbed the 
attention of many. There are also some other well- known ADR cases that were discovered 
postmarketing such as rosiglitazone (PPAR-y-agonist). Rosiglitazone has been associated with 
an increased risk of myocardial infarction, vigabatrine and visual field defects, tolcapone and 
risk of liver toxicity (Ferner & Butt, 2008; Stefan, Bernatik, & Knorr, 1999; Watkins, 2000). The 
growing number of incidences of ADR cases after the marketing of medicines, either serious or 
not, has raised an important question, to what extent do the existing systems and methods are 
effective in predicting the occurrence of ADRs (Lise Aagaard, Soendergaard, Andersen, 
Kampmann, & Hansen, 2007). Usually, a new medicine's information on the ADR profile 
progresses from observations conducted during the clinical development process. As we all 
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know, the gold standard for the study design is randomised controlled trials (RCTs) (Hansen, 
1990). However, RCTs were designed to focus more on measuring the efficacy of the drug and 
not detecting the ADRs as the outcome. Due to some characteristics of RCT design such as short 
periods of investigation, a small number of carefully determined participants in the trial, fixed 
drug doses, and controlled conditions and environment, a narrow limit was set for the detection 
of information about serious and unanticipated ADRs (Bisson, Gross, Miller, & Weller, 2003; 
Hansen, 1990, 1992). The data on common side effects, easily noticeable ADRs can be detected 
in RCTs. However, unfamiliar long term adverse reactions are hardly visible. Those unknown 
and rare ADRs can be detected through other pharmacovigilance research designs such as 
spontaneous reporting systems, case-control studies and cohort studies. This study is conducted 
to analyse the ADR data specifically related to drug-induced renal injuries in Malaysia based on 
the spontaneous ADR reports to National Pharmaceutical Control Bureau (hereafter NPCB). 
1.2 Problem Statement 
Declining renal function among patients who received drugs is a common cause of renal 
injuries. Drugs caused approximately twenty percent (20%) of community and hospital acquired 
episodes of acute renal failure (Bellomo, 2006). In Malaysia, it has been reported that drug-
induced renal injury is one of the top ten (10) types of ADR reported in Malaysia. Based on 
2014's report ("Official Portal National Pharmaceutical Control Bureau," 2014), from the total of 
11,921 ADR reports, 586 reports are related to urinary system disorders, which placed it as the 
lx most reported ADR based on the system organ class in Malaysia (Figure 1.1). On the other 
hand, in 2013, the reported ADR related to this organ system was 507 and it was in the 8* place 
(8* ranked) of the most reported ADR in Malaysia (Figure 1.2). The ranking has changed as it 
went up one place from 2013 to 2014. This shows that the incidence has increased and a closer 
view needs to be taken. To date, limited studies have been done to investigate the nephrotoxicity 
based on the spontaneous ADR reporting database in Malaysia. 
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1.3 Research Objectives 
1.3.1 General Objective 
To analyse the data on spontaneous adverse drug reactions reports related to drug-induced renal 
injuries and urinary system disorders in Malaysia from 2010 to 2014 
1.3.2 Specific Objectives 
There are four main specific objectives in this study which are: 
a) To describe the pattern / trend of adverse drug reaction related to drug-induced renal 
injuries spontaneously reported in Malaysia 
b) To identify the most common drug or the highest usage of drug that cause renal injuries 
to describe a relevant pattern of the reported adverse reactions 
c) To identify the predisposing factors/predictors which are susceptible to drug-induced 
renal injuries 
d) To explore potential preventive measure to prevent drug-induced renal injuries 
1.4 Research Question 
What is the most common drug that causes renal injuries to patients and what are the 
predisposing factors/predictors of drug induced renal injuries reported in Malaysia? 
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1.5 Statistical Hypothesis 
For this study, there are five null hypotheses that will be tested. They are: 
a) There is no association between the extent of renal injury and gender. 
b) There is no association between the extent of renal injury and race. 
c) There is no association between the extent of renal injury and groups of age. 
d) There is no association between the extent of renal injury and concomitant drugs. 
e) There is no association between the extent of renal injury and onset of reaction. 
1.6 Significance of the Study 
From this study, we will be able to identify the most common reported drug that causes 
renal injuries. Besides that, we will also be able to correlate and observe the relationship between 
the drug, predictors and the adverse event to be studied. 
1.7 Limitations of the Study 
There are certain limitations of this study that may influence the findings. The limitations 
that need to be considered in this study are as follows: 
a) Underreporting of data is possible as the data that will be collected are based on 
spontaneous adverse drug reporting - a passive method of ADR monitoring. There is no 
denominator to be compared to. 
b) The low quality of ADR reports may cause inadequate information and may have to be 
omitted from the analysis and may affect the results. The low quality of ADR reports may 
lead to the inability to draw a conclusion to drug-induced renal injury. Furthermore, 
variations in reports may cause a discrepancy in captured data and may result in 
inappropriate causality assessment. Incomplete data such as information about de-
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challenge re-challenge, onset of ADRs, dose, co-morbid disease and patient's medical 
history may complicate the analysis process. According to Perucca & Gilliam (2012), in 
population setting with natural and uncontrolled environment, it is hard to establish 
causality especially relevant information is missing or incomplete such as relation with 
dose, reversibility after drug discontinuation, and the effect of re-challenge or de-
challenge. 
1.8 Rationale of the Study 
Postmarketing surveillance on the effects of drugs in clinical practice is indispensable. 
Therefore, spontaneous reporting of ADRs is essential as it increases the knowledge of drug 
safety (Wyswski & Swartz, 2005). The data on collected spontaneous reporting can then be used 
in research, inferential statistics and evaluation of the quality of healthcare. 
The rationale of this study is to look into the developed renal problem due to the intake of 
drugs in Malaysia. By conducting this study, we can identify the prevalence of intended ADR 
and take precautions in order to prevent further episode and reduce the risk of the occurrence of 
drug-induced renal injuries. As stated by Cereza et al. (2010), the detection and evaluation of 
ADRs are required to increase the possibility of early identification of severe reactions, reactions 
of new drugs, increased frequency of known reactions, unknown effects, identification of the risk 
factors and possible dissemination of information among clinicians and health professionals. 
Through this study, it is hoped that preventive measures can be discovered and adopted by 
healthcare professionals while using the most common reported drug that causes renal problems. 
Drug-induced nephrotoxicity tends to be more common among certain patients and in specific 
clinical situations. Therefore, successful prevention requires comprehensive knowledge of 
pathogenic mechanisms of renal injury, patient-related risk factors, drug-related risk factors, and 
preemptive measures, coupled with vigilance and early intervention (Naughton, 2008). 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
In recent days, adverse drug reactions (ADRs) are a common and often preventable cause 
of hospital admission and in-hospital morbidity. ADRs have becoming an important challenge in 
today's modern medicine in terms of early recognition, proper management and avoid offensive 
practice. Adverse drug reactions can occur at any point of care in all settings where health care is 
offered and provided. 
As defined by World Health Organization (WHO, 1972), an ADR is known as "a 
response to a drug that is noxious and unintended and which occurs in doses normally used for 
the treatment, prophylaxis, or diagnosis of disease or the modification of physiological function. 
It is an unwanted effect experienced by patients or consumers who consume medicine (or 
combination of medicines) under normal setting of use. The emerged reactions could be a well -
known side effects or it could be a new and undetected beforehand. Side effect is defined by 
American Society of Health-System Pharmacists or ASHP (1995) as "an expected, well-known 
reaction resulting in little or no change in patient management. The examples of side effects are 
drowsiness or dry mouth due to administration of certain antihistamines, nausea associated with 
the use of antineoplastics or constipation due to the consumption of opiates. ASHP further 
defines side effect as 'an effect with a predictable frequency and an effect whose intensity and 
occurrence are related to the size of the dose ". Although such effects can be mild, they can also 
be serious and life-threatening. Side effects occur and presented as other than the intended 
therapeutic effect, whether beneficial, neutral or harmful. The term is sometimes considered 
synonymous with ADR, and is sometimes used to describe 'minor' and predictable ADRs. In 
addition, accidental poisoning, drug-abuse syndromes, drug withdrawal, and drug-over-dose 
complications should not be defined as ADRs. They may be regarded as adverse events. 
According to FDA, an adverse event is any undesirable experience associated with the use of a 
medical product in a patient ("Reporting Serious Problems to FDA - What is a Serious Adverse 
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Event?," 2014). Adverse event occurs while a patient is taking a drug and it is not necessary to 
determine whether the event was a response to the drug (Ferner & Butt, 2008). Adverse event 
may occur due to the devices or practices while the patient is given a drug. 
Adverse drug reactions can be categorised into several types of reactions. Based on the 
proposal of Rawlins and Thompson (1977), type A and type B of ADRs occur on the basis of the 
mechanism of action (Aronson & Ferner, 2003). Type A (augmented) reactions is common and 
related to the drug's pharmacological actions when given at the usual therapeutic dose and are 
normally dose-dependent. It is predictable from the known pharmacology of the drug. They are 
basically less severe and occur more frequently than type B events and are usually detected at 
some point in the clinical trials before the drugs are being marketed. An example is the 
anticholinergic effects which are associated with tricyclic antidepressants. On the contrary, Type 
B (bizarre) reactions are not due to an extension of the known active pharmacologic properties of 
the drug and are non-dose related. They are pharmacologically unexpected, unpredictable, or 
idiosyncratic adverse reactions and thus termed as bizarre. They are less common and often can 
only be discovered for the first time after a drug has already been made available for general use. 
An example is skin rashes which are caused by antibiotics. Despite that, it is sometimes difficult 
to allocate a reaction to one type. For instance, dose dependent (type A) nausea and vomiting 
caused by consuming erythromycin can also be categorised as type B as it is not 
pharmacologically predictable. 
J. K. Aronson (2002) has extended the classification to other alphabetically marked types 
to type C (dose and time dependent (chronic) reactions), type D (delayed reactions), type E 
(withdrawal reactions), and type F (failure of therapy). Types C, D, and E are not mechanisms 
but characteristics of their manifestations. Type C, or chronic reactions is related to the 
cumulative use of a drug. It has been suggested that Type C ADRs are connected with long-term 
drug therapies in which serious and common effects on public health takes place (Pirmohamed & 
Park, 2003; Rawlins & Thompson, 1977). An example of type C reaction is hypothalamic-
pituitary-adrenal axis suppression by corticosteroids (Rohilla & Yadav, 2013) . Type D, or 
'delayed' reactions, are time-related. The reaction becomes apparent sometime after the 
treatment. An example is teratogenesis e.g. vaginal adenocarcinoma with diethylstilbestrol and 
tardive dyskinesia caused by antipsychotic medication. Reactions which are associated with the 
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withdrawal of a medicine are known as Type E, or 'end-of-use' reactions. This type of reactions 
is known to emerge when the pharmacotherapy has been suddenly terminated and the best 
examples of this reaction are the withdrawal seizures on terminating anticonvulsant therapy and 
adrenocortical insufficiency following or as a subsequent to glucocorticoids termination. The 
last type is type F or 'failure' reactions which is often caused by drug interactions (Edwards & 
Aronson, 2000). 
A meta-analysis by Lazarou, Pomeranz and Corey (1998) found that, on the whole, the 
incidence of serious ADRs in the general hospitalised population in the United States was 6.7%, 
whereas the incidence of fatal ADRs was 0.32% among the patients from thirty-nine (39) 
prospective studies (Lazarou et al., 1998). Other studies in Europe estimated that the percentage 
of ADRs that led to hospitalisation in general population varies from a bare minimum of 1.8% in 
Netherlands to 3.6% in Italy, 6.5% in Great Britain, 8.4% in Denmark to a maximum of 12.8% in 
Greece (Farcas et al., 2010). However, the percentages are even higher when it comes to the 
population of elderly which ranges from 8.4% to 24% (Olivier et al., 2009; Passarelli, Jacob-
Filno, & Figueiras, 2005; Somers, Petrovic, Robays, & Bogaert, 2003). It is also apparent that 
ADRs may occur after the admission into the hospital which is reported to have been affecting 
up to 19.2%) of the patients (Davies, Green, Mottram, & Pirmohamed, 2006; Lagnaoui, Moore, 
Fach, Longy-Boursier, & Begaud, 2000). 
2.2 Overview of ADR reporting in Malaysia 
Patient safety outcomes can be contributed to the monitoring of ADRs through the 
execution of pharmacovigilance activities. It is known that spontaneous reporting of ADR is an 
important tool to gather safety information for the symptoms to be detected earlier. Spontaneous 
reporting course is a widespread method of drug surveillance and it is capable in recognising 
ADRs in the daily medical practice although it is known to have several disadvantages such as 
underreporting and absence of information on the number of people actually exposed to the drug. 
Reports received by each national pharmacovigilance centre will then be sent to the WHO 
Collaborating Centre for International Drug Monitoring to be compiled and analysed. 
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Malaysia's current reporting system of adverse drug reactions involves a passive 
approach where health care providers, pharmaceutical industries and patients or consumers can 
lodge their reports online or via prepaid postage report forms. The reports from marketing 
authorisation holders or pharmaceutical companies are compulsory whereas the reports from 
healthcare practitioners and consumers are on a voluntary basis. This voluntary basis is also well 
known as spontaneous reporting system of adverse drug reactions and it is one of the methods to 
increase the awareness and strengthen the knowledge of the health care key players as well as the 
consumer on the risks of medicines in clinical practice. This system of ADR reporting is the 
cheapest and easiest to establish and run. However, there are a few weaknesses following this 
system i.e. underreporting and bias (Hazell & Shakir, 2006). 
In Malaysia, National Centre for Adverse Drug Reaction which is based in NPCB, is a 
WHO-approved pharmacovigilance centre. It acts as a secretariat to Malaysian Adverse Drug 
Reactions Advisory Committee (MADRAC) and in 1990, it was accepted as the 30th member of 
the World Health Organisation (WHO) Program for International Drug Monitoring. MADRAC 
was established under Drug Control Authority (DCA) in order to carry out the function of 
pharmacovigilance for registered drugs in Malaysia. MADRAC monitors all types of drugs used 
by human such as vaccines, biologicals and herbal remedies and the records are maintained 
manually. MADRAC provides important information pertaining to local and international drug 
safety issues and also provides advice to DCA on risk management and risk communication 
subsequent to effective assessment of the benefit-risk profile of drugs. Other core functions of 
MADRAC include promoting ADR reporting in Malaysia, provide reliable information and 
advices to DCA on drug safety, disseminate drug safety information to healthcare professionals 
and participate in global pharmacovigilance activities via the WHO Programme for International 
Drug Monitoring. Under the WHO Program for International Drug Monitoring, MADRAC will 
receive and assess all adverse drug reactions reports and subsequently forward them to central 
WHO Global ICSR (individual case safety report) database. This database is maintained by the 
Uppsala Monitoring Centre (UMC), the WHO Collaborating Centre in Sweden. ("About the 
Malaysian Adverse Drug Reactions Advisory Committee," 2012). 
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Figure 2.1: Number of ADR reports sent to NPCB from 2000 until 2014 
The NPCB strives to ensure the safety of medicinal products registered in Malaysia 
through monitoring of ADR reports, identification and review of local and international drug 
safety issues, training and risk communication. Besides the traditional role of assessing ADR 
reports, NPCB conducted active surveillance to detect ADR signals which may indicate potential 
drug safety problems, monitored local and international drug safety issues, and implemented risk 
minimisation strategies. The number of ADR reports received by the NPCB has been steadily 
increasing since 2000. After being presented and approved at MADRAC meetings, the reports 
were submitted to be included in the WHO International Database of ADR reports. As seen in 
Figure 2, there was a 13.4% increase in the total number of ADR reports received in 2014 as 
compared to the previous year. This shows that the awareness of the importance of ADR 
reporting has increased and continues to rise. 
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2.3 Drug-induced renal disorders 
In present clinical practice, drug-induced renal disease constitutes as an important cause 
of acute renal failure and chronic renal disease. Renal injury occurs when kidney-specific 
detoxification and excretion do not work properly due to the damage or destruction of kidney 
function by exogenous or endogenous toxicants (Kim & Moon, 2012). Thus, drug-induced renal 
injury is the damage or destruction of kidney functions caused by the consumption of possible 
suspected drug or medication. Different classes of drugs or medicines initiate certain stereotyped 
kidney responses by virtue of immunological mechanisms or direct toxicity. For most patients 
suffering from drug-induced nephropathy, common risk factors which precipitate the adverse 
effects of kidney injury include: age, pre-existing renal dysfunction, volume-depleted state and 
coexisting use of other nephrotoxins. A few prototype drugs are well-recognised although it is 
impossible to present all the drugs that result in renal disease. A possibility of drug-induced renal 
failure should be kept as the prompt removal of the drug in a case of undiagnosed renal disease 
and supportive management can reverse the renal dysfunction to a large extent. 
In recent days, the incidence of drug-induced nephrotoxicity has been increasing with the 
ever increasing number of medicines and with easily obtained over-the-counter (OTC) medicines. 
Among the drugs reported to be major culprits to kidney damage include antibiotics, NSAIDs, 
angiotensin converting enzyme inhibitors (ACEI) and contrast agents. In an Indian study by Jha 
and Chugh (1995), drug-induced renal failure accounted for 20% of all acute renal failure in 
which most of it caused by aminoglycoside (accounted for around 40% of all acute renal failure 
cases). The four most common mechanisms of drug-induced nephrotoxicity include (1) 
vasoconstriction, (2) altered intraglomerular hemodynamics, (3) direct tubular toxicity, and (4) 
acute interstitial nephritis (Blatt & Liebman, 2013). Examples of symptoms that lead to renal 
disorders include pre-renal failure / functional renal failure, acute tubular interstitial, acute 
interstitial nephritis and drug-induced crystalluria (Ganguli & Prakash, 2003) 
Su, Hsieh and Gau (2007) conducted a study on drug drug-induced renal disorders based 
on spontaneous ADR reports. According to their study, they found that the most frequent 
reported suspected drugs in Taiwan were gentamicin (9.1%), followed by vancomycin (3.9%), 
warfarin (3.3%), amphotericin B (3.3%) and cyclosporin (2.8%). However, in most of the 
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literature reports, aminoglycoside antibiotics (AMGs), radiocontrast media, nonsteroidal anti-
inflammatory drugs, angiotensin-converting enzyme inhibitors, and diuretics are frequently 
implicated (Davidman, Olson, & Kohen, 1991). Table 2.1 shows mechanisms of drug-induced 
kidney injury with some examples. 
14 
Table 2.1: Mechanisms of drug-induced kidney injury with some examples 
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In an article, Bellomo (2006) indicated that drugs caused almost 20% of community and 
hospital acquired episodes of acute renal failure. As compared to three (3) decades ago, in 
average, patients nowadays are older, have more comorbidities (higher incidence of diabetes, 
cardiovascular disease and other chronic conditions), prescribed with multiple medications and 
are exposed to many diagnostic and therapeutic procedures and agents with the potential to harm 
kidney function. Some of these agents cause adverse drug effects that are linked to systemic 
toxicity including nephrotoxicity which results in serious clinical syndromes such as acute 
kidney injury (Pazhayattil, 2014). Uchino et. al (2005) reported in their study that nephrotoxic 
agents have been implicated as etiologic factors in 17%-26% of in-hospital acute kidney injury 
cases. A prospective study by Kohli Bhaskaran and Muthukumar (2000) found that among older 
adults, the incidence of drug-induced nephrotoxicity may be as high as 66%. The renal 
impairment can sometimes be reversible once the offending drug is stopped. However, the 
condition can be more costly, require several interventions and may necessitate hospitalization. 
Drugs causing renal injuries could exert their toxic effects through one or more pathogenic 
mechanisms and the injuries tend to be more frequent among patients in specific clinical 
conditions (Naughton, 2008). Among the pathophysiologic mechanism of renal injury include 
altered intraglomerular hemodynamics, tubular cell toxicity, crystal nephropathy, inflammation, 
thrombotic microangiopathy, and rhabdomyolysis (Schetz, Dasta, Goldstein, & Golper, 2005; 
Zager, 1997). It is important for health care professionals to have the knowledge on the drugs 
and their particular pathogenic mechanisms of kidney injuries so that it will be easy to recognise, 
manage and most importantly, to prevent the occurrence of drug-induce renal impairment. Based 
on the hospitalisation rates, morbidity, and mortality associated with renal impairment, 
knowledge of the typical agents associated with nephrotoxicity is critical in improving the ADR 
rates and outcomes (Waikar, Liu, & Chertow, 2008). Drug-induced renal impairment involves 
many classes of drugs and includes prescription agents as well as commonly encountered over-
the-counter drugs. 
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2.3.1 Classification of drug-induced nephrotoxicity 
Our kidneys are exposed to so many drugs. There are drugs with high concentration of 
drugs and their metabolites - thus, making the precious organs vulnerable to drug toxicity. As 
stated by Decloedt and Maartens (2011), drug-induced renal impairment contributes up to 25% 
of all cases of acute kidney injury. The injury caused by offending drugs may cause predictable, 
cumulative dose-dependent toxicity or idiosyncratic dose-independent toxicity at any time 
throughout treatment. Cumulative dose-dependent toxicity can be predicted and prevented. 
However, idiosyncratic dose-independent toxicity cannot be anticipated and avoided. A basic 
knowledge on drug-induced kidney disorder is really important in managing the toxicity and 
enables a vigilant approach in prescribing, dispensing and administering drugs that can 
potentially cause renal toxicity. 
Renal impairment may occur in different renal sites or compartments which may include 
the glomerulus, the renal vascular supply, and the tubulointerstitium where extensive tubular-
peritubular caplliary exchange of solutes takes place, as well as collecting ducts. Basically, the 
drug-induced renal toxicity is classified into four major renal syndromes which are (Decloedt & 
Maartens, 2011): 
1) Acute renal failure 
2) Chronic renal failure 
3) Glomerulonephritis 
4) Tubulopathies 
2.3.1.1 Acute renal failure 
Classically, acute renal failure (ARF) is defined as an "abrupt and sustained decrease in 
renal function" (Bouman & Kellum, 2010). The clinical condition of acute renal failure (ARF) 
is said to occur in anywhere from 1% to 25% of critically ill patients (Chertow, Levy, & 
Hammermeiter, KE, 1998; de Mendonca, Vincent, & Suter, PM, 2000) and it depends on the 
population being studied plus the criteria used to define its presence. A new classification 
scheme for acute kidney injury was established by the Acute Dialysis Quality Initiative (ADQI) 
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group. The group defines grades of increasing severity of acute renal injury into five class i.e. 
risk (class R), injury (class I) and failure (class F) - plus two outcomes class (loss and end-stage 
kidney disease). The classification system includes separate criteria for creatinine and urine 
output. As an example, Hoste et al (2007) used this classification scheme and they found that 
acute renal impairment occurred in 67% of ICU admissions with maximum R, I, F class of 12%, 
27% and 28%, respectively. Figure 4 summarises the ADQI consensus criteria for acute renal 
failure 
Figure 2.2: Proposed classification scheme for acute renal failure by ADQI 
Choudhury (2006) and Schetz et al. (2005) reported that nephrotoxicity due to drugs 
contributes to between 8-60% of acute renal injury cases in hospitalised patients. Elderly patients 
are likely more susceptible to acute renal injury from nephrotoxic agents related to the age-
related decline in glomerular filtration rate or renal blood leading to reduced clearance of the 
drug. Generally, drug-induced nephrotoxicity is reversible. However, given the high morbidity 
and mortality associated with acute renal impairment and the frequent and necessary use of drugs 
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in critically ill patients, clinicians should be aware of the potential nephrotoxicities and 
mechanisms (Rosner & Okusa, 2010). 
Drugs can induce acute renal injury by causing pre-renal, intrinsic or post-renal toxicity 
(obstructive nephropathy). Pre-renal toxicity occurs when the drugs impair the glomerular 
hemofiltration. Drugs can cause reduction of the renal blood perfusion by altering the vasomotor 
tone of the afferent (pre-glomerular) or efferent (postglomerular) arterioles and decrease the 
glomerular filtration rate with consequent renal failure. Patients with compromised renal 
perfusion (e.g. volume depletion or heart failure) are mostly at risk. Intrinsic renal or intrarenal 
disease is a type of kidney disease that often occurs when direct damage to the kidneys causes a 
sudden loss in kidney function. The disease also is caused by lack of blood to the kidneys, drug 
abuse and inflammation from other causes. 
Currently, there are still no standard guidelines used to infer changes in serum creatinine. 
Nevertheless, there a few biochemical criteria which have been used to indicate acute renal 
failure (Schoolwerth, Sica, Ballermann, & Wilcox, 2001). Those biochemical criteria include: 
1) a rise of 50% serum creatinine from baseline, or, 
2) an increase of 0.5 mg/dL (40 umol/L) or more when baseline serum creatinine is less than 
2 mg/dL (180 umol/L), or, 
3) an increase of 1 mg/dL (90 umol/L) or more if baseline creatinine is greater than 2 mg/dL 
2.3.1.2 Chronic renal failure 
Chronic kidney disease is the gradual loss of kidney function and the final stage of 
chronic kidney disease is called end-stage renal disease (ESRD). Chronic kidney disease leads to 
a buildup of fluid and waste products in the body. This condition affects most body systems and 
functions, including high blood pressure, low blood cell count, reduced vitamin D level and bone 
health. Chronic kidney failure does not usually cause symptoms until it reaches an advanced 
stage. It is usually detected at earlier stages by blood and urine tests. There are several main 
symptoms of advanced kidney disease which include tiredness, swollen ankles, feet or hands 
(due to water retention), shortness of breath, nausea and blood in the urine. 
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Slow progressive elevation of creatinine concentration is a presentation of drug-induced 
chronic renal failure. It also usually presented microscopically as tubulointerstitial nephritis. 
Tubulointerstitial nephritis is characterised by interstitial fibrosis, tubular atrophy and 
inflammation. Repeated or prolonged acute tubulointerstitial nephritis can direct to chronic 
tubulointerstitial disease. There are a few drugs known to be associated with chronic 
tubulointerstitial nephritis without acute episodes such as lithium and non-steroidal anti-
inflammatory drugs (NSAIDs) (Decloedt & Maartens, 2011). 
A classification of chronic kidney disorder has been established by The Kidney Disease 
Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation. Interestingly, this 
classification has been accepted and used worldwide. This classification defines chronic renal 
disease as a glomerular filtration rate (GFR) <60 mL/min/1.73 m2 or a GFR >60 mL/min/1.73 m2 
together with the presence of kidney damage for more than 3 months. By referring to this 
definition, the K/DOQI has recommended a classification of chronic renal disease to be further 
divided into 5 stages as seen in Table 1 below (Hassan, Al-ramahi, Aziz, & Ghazali, 2009). 
Table 2.2: Stages of Chronic Kidney Disease 
Stage 
1 
2 
3 
4 
5 
Description 
Kidney damage with normal or increased GFR 
Kidney damage with mild reduction in GFR 
Moderate reduction in GFR 
Severe reduction in GFR 
Kidney failure (end stage renal failure) 
GFRml/min/1.73m2 
>90 
60-89 
30-59 
15-29 
< 15 (need dialysis) 
2.3.1.3 Glomerulonephritis 
Glomerulonephritis is an inflammation, not an infection, of the tiny filters in the kidney 
(known as the glomeruli) that filter the blood coming to the kidney via the renal arteries. When 
the glomeruli are inflamed, red blood cells, white blood cells and protein escape into the urine. 
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However, this is usually detected by the doctor through the testing of the urine and finding traces 
of blood or protein ("Glomerulonephritis or nephritis," 2004). 
Glomerular dysfunction causes nephritic syndrome and it is marked by heavy proteinuria. 
Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primarily 
caused by podocyte dysfunction. Membranous glomerulonephritis (MGN) is characterised by 
subepithelial immune complex deposits in the glomerular basement membrane. This disorder 
tends to be present with proteinuria which can occasionally be severe (>2.5g per 24 hours). 
NSAIDs are the most common drug implicated and this complication can take place between 
several weeks to years after treatment initiation (Ranskov, 1999). The condition usually resolves 
after discontinuing drug therapy. However, continued NSAID therapy may lead to chronic renal 
impairment (Waring, 2006). Among other drugs which can cause MGN are captopril and 
penicillamine. 
2.3.1.4 Tubulopathies 
Tubulopathy is an impairment affecting the renal tubules of the nephrons. Renal 
tubulopathies form a complex group of rare disorders which result in the inability of the tubule to 
exert its various functions. Most of tubulopathies are hereditary, though some are acquired 
secondary to another disease or pharmacotherapy. Generally the consequences of tubular 
impairment are variable and is dependent on the location within the tubule and the existence, or 
not, of compensatory pathways. The usual clinical symptoms include loss in the urine of 
minerals, salts, vitamins; internal environment imbalance (Water balance, acid-base balance 
disorders for example) and delayed or defective growth (rickets, osteomalacia). 
2.4 Predisposing factors of drug-induced nephrotoxicity 
Older age, female sex are some of the predisposing factors stated in most literatures 
which are associated with lower total body water and reduced muscle mass. Decreased total body 
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water increases the concentration of drug in serum. Both factors work in concert to raise serum 
drug concentration to potentially toxic levels. In addition to these factors, hypoalbuminemia also 
carries the risk of inducing toxic drug levels by increasing the unbound drug fraction in the 
serum. Besides that, the risk of nephrotoxicity is increased in patients with acute kidney injury 
(AKI) or chronic kidney disease (CKD). Thus, patient who is on diuretic therapy or has vomiting 
or diarrhea that results in true volume depletion is vulnerable to toxic drug effects on the kidney. 
Similarly, patient with congestive heart failure or hepatic failure with ascites that has effective 
volume depletion may experience prerenal AKI and become more susceptible to the nephrotoxic 
effects of certain agents. This is because cirrhotic patients tend to have reduced muscle mass and 
hypoalbuminemia. Additional variables in older patients include comorbid conditions that 
predispose to AKI as well as an increased likelihood of polypharmacy with nephrotoxic drugs. 
Another group of age that is at particular risk for drug-induced renal impairment is 
neonates. In neonates, particularly those with premature delivery, drug nephrotoxicity bears a 
significant burden for AKI as compared to adult patients and is supported by data that suggest 
that drug-induced renal impairment leads to 16% of AKI cases in newborns. Several factors may 
explain this, including increased susceptibility of the neonatal immature kidney to nephrotoxic 
insults as well as the use of multiple nephrotoxic agents in critically ill newborns. 
Based on the previous study on the spontaneous reports by Jose and Rao (2006) in India, 
at least one predisposing factor was present in 79.9% of the reports whilein 90% of these reports, 
more than one predisposing factors were suspected to be involved. The most common 
predisposing factors identified that are associated in the reported reactions included 
polypharmacy and multiple disease state which was noticed in 93.1% and 52.9% of the reports, 
respectively. They found that among the reports with polypharmacy as a predisposing factor, 
mild, moderate and major polypharmacy were present in 25.8, 61.6, and 12.6% of the reports, 
respectively (Jose & Rao, 2006). 
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CHAPTER 3 
METHODOLOGY 
3.1 Research Design and Location of the Study 
This is a retrospective study where the data was collected at the Pharmacovigilance 
Section, Centre of Post Registration Product, National Pharmaceutical Control Bureau (NPCB). 
This study is descriptive in nature and relies on existing data. The data under observation are 
quantitative in nature. As stated in the "International Conference on Harmonization (ICH) of 
Technical Requirements for Registration of Pharmaceuticals for Human Use" (2003), a report in 
which unsolicited or voluntary contact is made between a regulatory agency and a reporter is a 
spontaneous report. According to the ICH guidelines, there are a few minimum reporting criteria 
for an ADR to be accepted and they include identifiable reporter, patient, at least one adverse 
event and one suspected drug or product. 
3.2 Sample Size Calculation 
For the purpose of this study, a sample size was not calculated as all spontaneous ADR 
reports from 2010 to 2014 related to the renal disorders were extracted from the Quest 2 database, 
regardless of the seriousness. Patient demographics, drug treatment and types of renal injuries 
were identified and recorded. 
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3.3 Validity of Data Collection 
In order to ensure the validity of data collection, ten (10) reports were initially sampled 
from the Quest 2 database (computerised data) and these data were compared (crosschecked) 
with the data from the original reports (hardcopy or softcopy form sent by the reporters). Data 
clarification with the experts or person- in- charge was also done. When there were some 
conflicts in the data (at least in one sample), another ten (10) reports were sampled. This process 
continued until all ten (10) sampled reports have no conflicts and in accordance with the original 
data. Once there was no discrepancy or conflict between those two softcopy and hardcopy data in 
any of the samples, the report sampling process was then stopped. 
3.4 Study Flow Chart 
Retrieved ADR reports related to drug induced renal 
injury from Quest 2 
Collected/extracted data for individual reports 
If incomplete, original ADR report form has been 
searched (hand search) 
Compiled and analysed data 
Discussion and final write-up 
Figure 3.1: Flow chart of the study process 
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3.5 Ethical Consideration 
The approval to commence this study was endorsed by the Research Ethics Committee 
(REC) of Universiti Teknologi MARA (UiTM) in order to ensure that the research project is 
conducted in compliance with the national and international conditions and guidelines stipulated 
in the Good Clinical Practice Guideline, Ministry of Health (MOH), Malaysia and the 
Declaration of Helsinki, World Medical Association (WMA). An approval from the Research 
and Ethics Committee (MREC) of the Malaysian Ministry of Health was also obtained as this 
project will be conducted in the facilities of MOH. Furthermore, this study was registered under 
National Medical Research Registry (NMRR), approved by the Clinical Research Centre (CRC) 
Ministry of Health Malaysia and was given with registration ID NMRR-15-203-24512. 
A formal letter was given by the pharmacy faculty, UiTM to the Director of Regulatory 
Pharmacy, NPCB before the study was conducted. All the data that were obtained from the 
Quest 2 database such as patients' profile and medical records were restricted only for the 
investigators and were ensured to be kept private and confidential. 
3.6 Data Collection 
The following information was taken into consideration: (1) source of reports, (2) 
reporter's designation, (3) patient's age and gender, (4) reporter's diagnosis of the ADR, (5) drug 
exposure (indication and dosage), (6) concomitant drugs, (7) time of event onset, (8) outcome of 
the ADR and also (9) the types of renal injury. Reports were classified according to the WHO 
criteria for causality assessment. By referring to the WHO Adverse Reaction Terminology 
(2012), the types of renal injury were determined according to system organ class (SOC) of 
urinary system disorders. Drugs involved in the ADRs were codified into various drug classes 
according to anatomical therapeutic chemical (ATC) classification based on WHO-ATC Index 
2005. 
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3.6.1 ADR Causality Assessment and Extent of Severity 
For each ADR report submitted to MADRAC, the causality assessment is classified into Certain, 
Probable, Possible, Unlikely and Unclassifiable. The classification is made based on the WHO-Uppsala 
Monitoring Centre (WHO-UMC) guidelines on causality assessment (WHO-UMC 2005). The extent of 
severity was recorded based on the severity proclaimed by the reporters and was classified as mild, 
moderate and severe. 
3.6.2 Patient Characteristics 
Patients' age, gender, race and number of concomitant drugs received (or polypharmacy) 
were all considered and evaluated in this study. In agreement with the previous paper by Gallelli 
et al. (2002), patients will be subdivided into six age groups; infants, children and adolescents (0-
15 years), young adults (16-30 years), adults (31-45 years), older adults (46-60 years), elderly 
adults (61-75 years), and very elderly adults (over 75 years). Based on the description and 
characterisation by Veehof, Stewart, Haaijer-Ruskamp and Jong, (2000), polypharmacy is 
considered as minor (0-3 drugs), moderate (4-5 drugs) or major (>5 drugs). 
3.6.3 Onset of Time to Renal Injury 
As described by Hoigne et al. (1990) the onset of reactions time was distinguished into 
three categories; acute (from 0 to 60 minutes), sub-acute (from 1 hour to 24 hours) and latent 
(more than 24 hours). 
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3.7 Data Selection Criteria 
3.7.1 Inclusion criteria 
a) All ADR reports related to drug-induced renal injury (classified as 'urinary system 
disorders' based on System Organ Class (SOC) of the ADR terminology of the WHO) 
reported to NPCB from 2010 until 2014 
b) ADR reports with reactions that were classified as containing Certain, Probable, Possible, 
Unlikely and Unclassifiable causal relationship with the drug (regardless of the severity) 
according to the WHO Causality Assessment / Categories. 
3.7.2 Exclusion criteria 
a) All ADR reports which are non-related to drug-induced renal injuries reported to NPCB. 
b) ADR reports which are based on literature reports. 
c) ADR reports related to the use or administration of vaccines. 
d) ADR reports related to the use or administration of traditional and complementary 
medicines. 
3.8 Data Analysis 
3.8.1 Descriptive Statistical Analysis 
The data were analysed using Microsoft Excel and Statistical Package for Social Science 
(SPSS) version 22 software. Descriptive statistical analyses were carried out to describe the 
demographic data and pattern or trends of the drug induced renal injuries reported in Malaysia. A 
descriptive analysis was also done on reported drugs that are common in causing renal injury in 
Malaysia. Mean, standard deviation (SD) and the percentage were determined and presented. 
27 
3.8.2 Inferential Statistical Analysis 
The null hypotheses mentioned earlier were tested by using Pearson's chi-square test in 
order to determine the association between the studied variables (e.g. age, gender, race, 
concomitant drugs) with the extent of severity. A significance level was set at a=0.05. A p-value of 
<0.05 is considered statistically significant. 
Factors which could have predisposed to the occurrence of renal impairment were also 
evaluated. Predisposing factors that were considered for the purpose of this study include age, 
gender, race, dosage of the drug, number of concomitant drugs (polypharmacy) and the 
combination of drugs. Multiple logistic regressions were applied to determine the association 
between predisposing factors of drug induced renal injuries with the extent of severity. Analyses on 
the relationship of the intended ADR with the predictors (independent variables) were 
statistically analysed using simple logistic regression (univariate analysis) and binary logistic 
regressions (multivariate analysis). All variables that scored a p-value which is less than 0.25 
during univariate analysis were included in the multivariate analysis. The backward and forward 
stepwise logistic regressions were run and used for the variable under interest (extent of severity) 
which was binary. The final model was checked by using the Hosmer-Lemeshow test. The analyses 
were presented with adjusted odds ratios with 95% confidence intervals, Wald statistics and p-value 
where necessary. Again, significance level was set at a=0.05 and a p-value of <0.05 was considered 
statistically significant. 
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CHAPTER 4 
RESULTS 
4.1 Pattern / trend of adverse drug reaction related to drug induced renal injuries 
spontaneously reported in Malaysia (2010 - 2014). 
4.1.1 Pattern /trend of ADR reports in Malaysia according to sources of reports 
In the 5-years period from January 2010 until December 2014, a total of 2093 reports 
which is related to drug-induced renal injuries were extracted from the Quest 2 database. After 
the removal of possible duplications and exclusion of reports derived from literatures, a finalised 
number of 1874 reports were considered to be analysed throughout this study. From the report, 
since more than one drug might be implicated in a report, 2086 drugs were recorded as the 
suspected drugs that induced renal injuries (1.11 drugs per report). 
According to the sources of reports, Selangor was found to be the state with the highest 
number of reports sent to NPCB (n = 389; 20.8%). This is followed by Kuala Lumpur (n = 207; 
11%) and Perak (n = 186; 9.9%). Table 4.1 shows the number of drug-induced renal injuries 
reported in Malaysia according to states in Malaysia. By institutions (Table 4.2), government 
hospitals sent the highest number of reports with a number of 1334 reports (71.2%). Private 
sectors were led by the pharmaceutical companies with a total number of reports of 183 (9.8%). 
Almost sixty-seven percent of the reports (n = 1249) were sent by pharmacists, followed by 
medical officers that are working in government hospitals (n = 246, 13.1%). The trend of drug-
induced renal injuries report is shown in Table 4.3. 
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Table 4.1: Trends of ADR related to drug-induced renal injuries reported according to states in 
Malaysia 
State 
WP Labuan 
Perlis 
Kelantan 
Kedah 
Terengganu 
Pahang 
Johor 
Sarawak 
Melaka 
N Sembilan 
P Pinang 
Sabah 
Perak 
WP Kuala Lumpur 
Selangor 
Missing Data 
Data (N = 1874) 
n 
13 
15 
57 
62 
69 
83 
99 
106 
112 
138 
144 
171 
186 
207 
389 
23 
% 
0.7 
0.8 
3.0 
3.3 
3.7 
4.4 
5.3 
5.7 
6.0 
7.4 
7.7 
9.1 
9.9 
11.0 
20.8 
1.2 
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Table 4.2: Number of drug-induced renal injuries reported in Malaysia according to institutions 
Institution 
Community pharmacy 
Dental clinic 
Private clinic 
University hospital 
Private hospital 
Pharmaceutical company 
Government clinic 
Government hospital 
Missing data 
N = 1874 
n 
1 
1 
4 
35 
37 
183 
272 
1334 
7 
% 
0.1 
0.1 
0.2 
1.9 
2.0 
9.8 
14.5 
71.2 
0.4 
Table 4.3: Number of drug-induced renal injuries reported in Malaysia according to reporter's 
designation 
Designation 
Dentist 
General practitioner (GP) 
Medical assistant (MA) 
Housemen (HO) 
Nurse 
Consultant 
Specialist 
Provisional registered pharmacist (PRP) 
Pharmaceutical company 
Medical officer (MO) 
Pharmacist 
Missing data 
(N = 1874) 
n 
1 
1 
1 
4 
5 
6 
39 
56 
183 
246 
1249 
83 
% 
0.1 
0.1 
0.1 
0.2 
0.3 
0.3 
2.1 
3.0 
9.8 
13.1 
66.6 
4.4 
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4.1.2 Pattern / trend of ADR reports in Malaysia according to patients' demography 
According to the patients' demography (as presented in Table 4.4), fifty-two percent 
(52%>) of the patients with the studied ADRs were women and almost half of them (n = 927; 
49.5%) were Malay, followed by Chinese with 16.8% (n = 315), Indian with 12.8% (n = 239) 
and other races with 9.0% (n = 168). Out of 1874 reports, 225 (12.0%) of the ADR reports have 
missing data in terms of the race of patients. The mean age of patients was 42.97 (SD ± 21.49). 
Patients within 46 to 60 years old were found to be highest group of patients reported with drug-
induced renal injuries (n = 501; 24.1%). Patients who are more than 75 years old were found to 
be the least reported patient with ADRs related to drug-induced renal injury (n = 76; 4.1%>). Chi 
square tests were conducted to point out the association between patient related risk factors and 
the extent of severity. The results showed that there is no association between gender (P = 0.181), 
race (P = 0.269) and age groups (P = 0.563) with the extent of severity (Table 4.5). 
Table 4.4: Data of ADR related to drug-induced renal injuries reported in Malaysia according to 
patients' demography 
Characteristics 
Gender 
Male 
Female 
Not reported 
Race 
Malay 
Chinese 
Indian 
Others 
Not reported 
Data (N = 
No. (%) of ADR reports 
847 (45.2) 
976(52.1) 
51 (2.7) 
927 (49.5) 
315(16.8) 
239(12.8) 
168 (9.0) 
225 (12.0) 
=1874) 
Characteristics 
Age group 
Oto 15 
16 to 30 
31 to 45 
46 to 60 
61 to 75 
>75 
No. (%) of ADR reports 
240 (12.8) 
291 (15.5) 
452(24.1) 
501 (26.7) 
314(16.8) 
76(4.1) 
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Table 4.5: Chi square test of association between risk factors and severity of renal injury 
Variables 
Gender 
Male 
Female 
Extent of Injury [n (%)] 
Mild 
219 (28.2) 
290 (32.3) 
Moderate 
421 (54.2) 
461 (51.4) 
Severe 
p value 
137 (17.6) 
146 (16.3) 
0.181 
Age (Years) 
- 0-15 
- 16-30 
- 31-45 
- 46-60 
- 61-75 
- >75 
61 (26.9) 
97 (34.3) 
122 (33.1) 
132 (28.4) 
85 (29.4) 
19 (33.9) 
124 (54.6) 
142 (50.2) 
191 (51.8) 
262 (56.3) 
144 (49.8) 
25 (44.6) 
42 (18.5) 
44 (15.5) 
56 (15.2) 
71 (15.3) 
60 (20.8) 
12 (21.4) 
0.269 
Race 
- Malay 
- Chinese 
- Indian 
- Others 
277 (55.6) 
88 (17.7) 
81 (16.3) 
52 (10.4) 
488 (57.2) 
159 (18.6) 
123 (14.4) 
83 (9.7) 
145 (55.6) 
56 (21.5) 
30 (11.5) 
30 (11.5) 
0.563 
Chi-square test, p<0.05 as significant at 95% CI 
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4.1.3 Analysis of ADR reports according to causality and extent of severity 
Upon causality assessment, it was found that more than three-quarter of the reports (n = 
1606, 85.7%o) were classified as possible, followed by probable (10.7%>) and certain (3.3%>). 
From the reported reactions, almost half of the cases were reported with a moderate extent of 
severity (47.4%). Mild reactions accounted for 27.5% while only 15.2% of the reactions were 
deemed to be severe as presented in Table 4.6. 
Table 4.6: Analysis of ADR related to drug-induced renal injuries reported in Malaysia 
according to reaction's causality and the extent of severity 
Parameters 
Data (N = 1874) 
Number (%) of ADR 
Causality 
-CI (Certain) 62(3.3) 
- C2 (Probable) 200 (10.7) 
- C3 (Possible) 1606 (85.7) 
- C4 (Unlikely) 3 (0.2) 
- C5 (Unclassifiable) 3 (0.2) 
Extent of severity 
-Mild 516(27.5) 
- Moderate 888 (47.4) 
- Severe 285 (15.2) 
-Not reported 185(9.9) 
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4.1.4 Number of concomitant drugs 
As depicted in Table 4.7, among the reports with concomitant drugs, mild, moderate and 
major use of multiple drugs were present in 90.6%>, 6.6%> and 281%) of the reports respectively. A 
majority of the reports stated that the use of multiple drugs does not exceed 3 drugs. Chi square 
test showed that there is a significant association between concomitant drug groups and the 
extent of severity. The result of the test (as shown in Table 4.8) pointed out that the group of 0 -
3 drugs has a higher occurrence of severe type of reactions (76.1%>; P = < 0.001). 
Table 4.7: Analysis of ADR reports according to number of concomitant drug groups 
Number of concomitant drug groups n 
1698 
123 
53 
Data (N = li 874) 
% 
90.6 
6.6 
2.8 
0 -3 drugs (mild) 
4 - 5 drugs (moderate) 
> 6 drugs (major) 
Table 4.8: Chi square test of association between concomitant drug groups and severity of renal 
injury 
Variable Extent of Injury [n (%)] p value 
Concomitant drug groups 
0 - 3 drugs 
4 - 5 drugs 
> 6 drugs 
Mild 
463 (89.7) 
24 (4.7) 
29 (5.6) 
Moderate 
753 (84.8) 
63 (7.1) 
72(8.1) 
Severe 
217(76.1) 
29(10.2) 
39(13.7) 
< 0.001 
Chi-square test, p<0.05 as significant at 95% CI 
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4.1.5 Trends of onset of time to renal injury reported in Malaysia 
Table 4.9 presents the data of drug-induced renal injuries according to the onset of 
reaction time. Most of cases were reported with sub-acute reaction (n = 730; 39.0%), followed by 
latent reactions (n = 475; 25.3%) and acute reactions (n = 275; 14.7%). A chi square test was 
done to determine the association between onsets of time category and the extent of severity 
(Table 4.10). The test proved that there is a significant association between onsets of time 
category and the extent of severity (P = < 0.001) where the latent onset of time has a higher 
occurrence of severe adverse reactions (41.6%). 
Table 4.9: Analysis of renal injuries according to the onset of time 
Onset of time category 
Data (N = 1874) 
n % 
Acute 275 14.7 
Sub-acute 730 39.0 
Latent 475 25.3 
Not reported 394 21.0 
Table 4.10: Chi square analysis of association between onsets of time with the extent of severity 
Variable Extent of Injury [n (%)] p value 
Mild Moderate Severe 
Onset of time category 
- Acute 71 (16.9) 156 (20.5) 44 (18.5) < 0.001 
- Sub-acute 250 (59.5) 367 (48.3) 95 (39.9) 
- Latent 99 (23.6) 237 (31.2) 99 (41.6) 
* Chi-square test, p<0.05 as significant at 95% CI 
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4.1.6 Analysis of ADR reports according to outcome of the ADRs 
In a majority (67.1%) of the reports, patients experienced a definite improvement after 
the dechallenge (omission or decrease in dose) of the suspected drugs. 17.3% of the patients did 
not improve after dechallenge action. Only 1.9% of the cases where the medications were still 
continued and no dechallenge were done. After rechallenge, 35 of the 45 cases (1.9%) had 
recurrence of symptoms. Most of the reports (95.5%) recorded that no rechallenge was 
performed. In 66.3% of the reports, as the final outcome, the patients recovered without sequele 
from the reactions at the time of the reporting of the ADR. Out of 1874 ADR reports received, 
342 cases (18.2%) have not yet recovered from the ADR at the time of reporting. Death cases 
were also reported where 10 cases (0.5%) may be contributed by the drug, 3 cases (0.2%) were 
due to the adverse reactions or renal injuries and 8 cases (0.4%) were reported unrelated to the 
use of the drugs. Table 4.11 summarises the analysis of ADR related to drug-induced renal 
injuries reported in Malaysia according to the outcome of related ADRs. 
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Table 4.11: Analysis of ADR related to drug-induced renal injuries reported in Malaysia 
according to the outcome of related ADRs 
Outcome 
Data (N = 1874) 
Number (%) of ADR 
After dechallenge 
Definite improvement 1258(67.1) 
No improvement 3 24 (17.3 ) 
Medication continued 36(1.9) 
Unknown 256(13.7) 
After rechallenge 
Recurrence of symptoms 35 (1.9) 
No recurrence of symptoms 10 (0.5) 
No rechallenge performed 1790 (95.5) 
Unknown 39(2.1) 
Final outcome 
Recovered without sequele 1243 (66.3) 
Recovered with sequele 2 (0.1) 
Death - drug may be contributory 10 (0.5) 
Death - due to adverse reaction 3 (0.2) 
Death - unrelated to drug 8 (0.4) 
Not yet recovered 342 (18.2) 
Unknown 266 (14.2) 
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4.1.7 Types of ADR related to drug induced renal injuries reported in Malaysia 
Overall, 85 types of renal injuries were reported and recorded along this study. One 
report may have more than one type of renal injury cases. Out of 1904 cases, face oedema was 
found to be on the top of the list with more than half (n = 1157, 60.8%) of cases reported. This is 
followed by creatinine blood increase (n = 173, 9.1%) and haematuria (n = 112, 5.9%) at second 
and third place respectively. Table 4.12 shows the data of top 20 renal injuries that were reported 
in Malaysia from 2010 until 2014. 
Table 4.12: Data of top 20 types of ADR related to renal injury reported in Malaysia 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
Types of renal injury 
Face oedema 
Creatinine blood increased 
Haematuria 
Renal failure acute 
Renal impairment 
Urinary retention 
Urinary frequency 
Urine discolouration 
Dysuria 
Nocturia 
Urea blood level increased 
Renal function abnormal 
Polyuria 
Difficulty in micturition 
Creatinine clearance decreased 
Urinary incontinence 
Urine abnormal 
Proteinuria 
Urinary tract infection 
Renal function tests nos abnormal 
(N = 
n 
1157 
173 
112 
66 
38 
27 
25 
23 
22 
19 
19 
17 
13 
12 
10 
10 
10 
9 
9 
7 
1904) 
% 
60.8 
9.1 
5.9 
3.5 
2.0 
1.4 
1.3 
1.2 
1.2 
1.0 
1.0 
0.9 
0.7 
0.6 
0.5 
0.5 
0.5 
0.5 
0.5 
0.4 
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4.2 Common drugs causing drug induced renal injuries reported in Malaysia (2010 - 2014) 
4.2.1 Pharmaceutical groups 
Based on the ADR data collected, an analysis of common drugs that causes drug-induced 
renal injuries was done. It was found that a total of 31 pharmaceutical groups were reported to 
cause renal injuries in Malaysia. A brief comparison of the top 10 pharmaceutical groups across 
the years 2010 till 2014 was also done in order to look at the pattern of the reported 
pharmaceutical groups. As presented in Table 4.13, it can be seen that cardiovascular agents, 
anti-infectives and analgesics are the three groups that are present in the top three of the lists. In 
2010, cardiovascular had been on the top of the list. However, the ranking had dropped to the 
third place in 2012 and maintained that position until 2014. On the other hand, analgesics which 
was in the third place in 2010, has become the most reported pharmaceutical group to induce 
renal injuries in 2014. In total, from 2010 until 2014, it was found that analgesic is the highest 
number of pharmaceutical group reported to cause renal injuries (n = 496; 23.78). This is 
followed by anti-infectives (n = 448; 21.48%) and cardiovascular agents (n = 380; 18.22%) at the 
second and third place respectively. Table 4.14 shows the analysis of drugs that caused renal 
injuries which is reported in Malaysia according to pharmaceutical groups from 2010 until 2014. 
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Table 4.13: Comparison of top 10 drugs caused renal injuries across years 2010 till 2014 (according to pharmaceutical groups) 
Year 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
2010 
Pharm. group 
Cardiovascular 
Antiinfectives 
Analgesic 
Anticoagulant 
Others 
Antineoplastic 
Antiepileptic 
Antidiabetic 
Anti-
hyperlipidemic 
Antituberculosis 
n 
83 
61 
53 
21 
17 
15 
10 
8 
7 
6 
2011 
Pharm. group 
Cardiovascular 
Analgesic 
Antiinfectives 
Others 
Anti-
hyperlipidemic 
Anticoagulant 
Antidiabetic 
Antiviral 
Antineoplastic 
Hormone 
n 
79 
76 
65 
17 
15 
12 
6 
6 
5 
5 
2012 
Pharm. group 
Analgesic 
Antiinfectives 
Cardiovascular 
Anti-
hyperlipidemic 
Antineoplastic 
Others 
Anticoagulant 
Antiviral 
Antidiabetic 
Antituberculosis 
n 
103 
85 
78 
20 
18 
16 
13 
11 
9 
8 
2013 
Pharm. group 
Antiinfectives 
Analgesic 
Cardiovascular 
Others 
Anti-
hyperlipidemic 
Antineoplastic 
Antidiabetic 
Anticoagulant 
Immunosuppresive 
agent 
Antiepileptic 
n 
126 
122 
75 
30 
23 
21 
19 
14 
14 
10 
2014 
Pharm. group 
Analgesic 
Antiinfectives 
Cardiovascular 
Others 
Antidiabetic 
Immunosuppresive 
agent 
Anti-
hyperlipidemic 
Antineoplastic 
Antiviral 
Antiepileptic 
n 
142 
111 
65 
27 
17 
16 
13 
13 
13 
12 
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Table 4.14: Overall analysis of drugs caused renal injuries reported in Malaysia according to 
pharmaceutical groups from 2010 until 2014 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
Pharmaceutical group 
Analgesic 
Antiinfectives 
Cardiovascular 
Others 
Antihyperlipidemic 
Antineoplastic 
Anticoagulant 
Antidiabetic 
Antiepileptic 
Immunosuppresive agent 
Antituberculosis 
Antiviral 
Antipsychotic 
Antiasthmatic 
Antihistamine 
Vitamin 
Antigout 
Antidepressant 
Antiulcer 
Minerals 
Corticosteroid 
Hormone 
Antispasmodic 
Contrast media 
Antirheumatic 
Anesthetic 
Antiemetic 
Eye preparations 
Antihypertensive 
Antivenom 
Dermatological 
Data (N = 2085) 
n 
496 
448 
380 
107 
78 
72 
70 
59 
42 
41 
37 
36 
31 
26 
20 
18 
17 
15 
13 
13 
12 
11 
9 
9 
7 
6 
6 
2 
1 
1 
1 
% 
23.78 
21.48 
18.22 
5.13 
3.74 
3.45 
3.36 
2.83 
2.01 
1.97 
1.77 
1.73 
1.49 
1.25 
0.96 
0.86 
0.81 
0.72 
0.62 
0.62 
0.58 
0.53 
0.43 
0.43 
0.34 
0.29 
0.29 
0.10 
0.05 
0.05 
0.05 
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4.2.2 Generic names 
The collected data were further analysed for common drugs inducing renal injuries according to the generic names of the drugs. 
From the descriptive analysis, it was found that a total of 346 types of generic were reported and comparisons of top 10 generics were 
done from the year 2010 until 2014. In Table 4.15, it can be observed that since 2011 till 2014, diclofenac has always been at the top 
of the list as compared to other generics. It never fails to come in first place and the number of reports also has increased from year to 
year. The number of cases and the ranking of ibuprofen as one of the most common drug causing renal injuries also kept increasing 
from 2010 until 2014. 
Table 4.15: Comparison of top 10 drugs caused renal injuries across years 2010 till 2014 (according to generic names) 
Year 
No 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
2010 
Generic name 
Aspirin 
Diclofenac 
Perindopril 
Enoxaparin 
Ibuprofen 
Amlodipine 
Paracetamol 
Clopidogrel 
Fondaparinux 
Gentamicin 
n 
20 
17 
16 
10 
10 
9 
9 
6 
6 
6 
2011 
Generic name 
Diclofenac 
Paracetamol 
Amlodipine 
Ibuprofen 
Aspirin 
Perindopril 
Amoxycillin 
Cloxacillin 
Dabigatran 
Erythromycin 
n 
21 
18 
16 
16 
15 
11 
8 
7 
6 
6 
2012 
Generic name 
Diclofenac 
Aspirin 
Paracetamol 
Ibuprofen 
Amlodipine 
Perindopril 
Amoxycillin 
Cloxacillin 
Lovastatin 
Mefenamic acid 
n 
36 
19 
15 
13 
11 
11 
10 
10 
9 
9 
2013 
Generic name 
Diclofenac 
Ibuprofen 
Aspirin 
Paracetamol 
Amoxycillin 
Cloxacillin 
Mefenamic acid 
Amlodipine 
Naproxen 
Simvastatin 
n 
35 
27 
24 
18 
16 
14 
12 
11 
10 
10 
2014 
Generic name 
Diclofenac 
Ibuprofen 
Paracetamol 
Mefenamic acid 
Amoxycillin/clavulanate 
Cloxacillin 
Perindopril 
Amlodipine 
Aspirin 
Methotrexate 
n 
43 
29 
20 
19 
16 
16 
16 
14 
14 
12 
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Overall, from 2010 until 2014, still, it was found that diclofenac has the highest number 
of reports that cause renal injuries (n = 152; 7.3%) as compared to other generics. This is 
followed by ibuprofen (n = 95; 4.6%) in second place and aspirin or acetyl salicylic acid (n = 92; 
4.4%) in the third position. Table 4.16 illustrates the analysis of drugs which cause renal injuries 
that are reported in Malaysia according to generic names from 2010 until 2014. 
Table 4.16: Analysis of top 20 drugs caused renal injuries reported in Malaysia according to 
generic names from 2010 until 2014 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
Generic name 
Diclofenac 
Ibuprofen 
Aspirin 
Paracetamol 
Amlodipine 
Perindopril 
Cloxacillin 
Mefenamic acid 
Amoxycillin 
Amoxycillin/clavulanate 
Lovastatin 
Methotrexate 
Simvastatin 
Naproxen 
Ceftriaxone 
Vancomycin 
Cefuroxime 
Erythromycin 
Etoricoxib 
Gentamicin 
n 
152 
95 
92 
80 
61 
61 
52 
47 
45 
34 
30 
28 
27 
26 
25 
25 
24 
23 
22 
21 
% 
7.3 
4.6 
4.4 
3.8 
2.9 
2.9 
2.5 
2.3 
2.2 
1.6 
1.4 
1.3 
1.3 
1.2 
1.2 
1.2 
1.2 
1.1 
1.1 
1.0 
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4.2.3 Analysis of most common drug causing renal injuries (2010 - 2014) 
Further analyses were conducted to identify the pattern of ADR reports related to renal 
injuries and was done on the most common drug inducing renal injury i.e. diclofenac. In this 
study, the age group of patients' age that uses diclofenac is from 1 to 81 years old. Therefore, 
the mean age for patients with related ADRs were 38.5 years old (SD ± 17.5) and more than half 
(57.9%) were women. The group of age which used diclofenac the most is between 16 to 30 
years old (32.2%). Most of the patients reported to have renal injuries were Malay (57.2%). 
Based on the causality assessments of the reports, it was found that 71.7% of the reports 
indicated that most of the reactions were classified as possible. In terms of extent of severity, it 
can be observed that the moderate type of severity is the most reported reaction (as shown in 
Table 4.18). More than half of the cases were reported as moderate for diclofenac (n = 85; 
55.9%). 
Table 4.17: Data of ADR related to diclofenac-induced renal injuries reported in Malaysia 
according to patients' demography 
(N = 152) 
Characteristics No. (%) of ADR reports Characteristics No. (%) of ADR reports 
Gender 
Male 64(42.1) 
Female 88 (57.9) 
Race 
Malay 87 (57.2) 
Chinese 21 (13.8) 
Indian 30 (19.7) 
Others 13 (8.6) 
Not reported 1 (0.7) 
Age group 
Oto 15 
16 to 30 
31 to 45 
46 to 60 
61 to 75 
>75 
13 (8.6) 
49 (32.2) 
34 (22.4) 
35 (23.0) 
20(13.2) 
1 (0.7) 
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Table 4.18: Analysis of ADR related to diclofenac-induced renal injuries reported according to 
reaction's causality and the extent of severity 
Parameters 
Causality 
- CI (Certain) 
- C2 (Probable) 
- C3 (Possible) 
- C4 (Unlikely) 
- C5 (Unclassifiable) 
Extent of severity 
-Mild 
- Moderate 
- Severe 
- Not reported 
(N = 152) 
Number (%) of ADR 
14 (9.2) 
29(19.1) 
109(71.7) 
-
-
46 (30.3) 
85 (55.9) 
19(12.5) 
2(1.3) 
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According to the analyses of outcome of the ADRs, it can be noticed that most patients 
experienced a definite improvement after the dechallenge (omission or decrease in dose) of the 
suspected drugs. Only a few patients did not improve after the dechallenge with 15.8%. Besides 
that, it also can be observed that no rechallenge activity was performed in almost all cases 
reported for diclofenac (96.7%). As the final outcome, about three-quarter of the patients had 
recovered without sequele from the adverse reactions. Table 4.19 summarises the analysis of 
ADR related to diclofenac-induced renal injuries reported according to the outcome of related 
ADRs. 
Table 4.19: Analysis of ADR related to diclofenac-induced renal injuries according to the 
outcome of related ADRs 
Diclofenac (N = 152) 
Outcome 
Number (%) of ADR 
After dechallenge 
Definite improvement 119 (78.3) 
No improvement 24 (15.8) 
Unknown 9 (5.9) 
After rechallenge 
Recurrence of symptoms 1 (0.7) 
No recurrence of symptoms 3 (2.0) 
No rechallenge performed 147 (96.7) 
Unknown 1 (0.7) 
Final outcome 
Recovered without sequele 118 (77.6) 
Not yet recovered 25 (16.4) 
Unknown 9 (5.9) 
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Table 4.20 presents the data of diclofenac-induced renal injuries according to the onset of 
reaction time. Most of cases were reported with sub-acute reaction (48.7%) and followed by 
acute reactions (30.3%) and latent reactions (5.3%). 
Table 4.20: Analysis of renal injuries caused by diclofenac according to the onset of time 
Onset of time category 
Acute 
Sub-acute 
Latent 
Not reported 
Diclofenac (N = 152) 
Number (%) of reports 
46 (30.3) 
74 (48.7) 
8 (5.3) 
24 (15.8) 
Chi square test was also done to relate the association between the onsets of time and the 
extent of severity. However, the result indicates that there is no significant association between 
the two variables (P = 0.308). 
Table 4.21: Chi square analysis of association between onsets of time with the extent of severity 
Variable Extent of Injury [n (%)] 
Chi-square test, p<0.05 as significant at 95% CI 
p value 
Onset of time category 
- Acute 
- Sub-acute 
- Latent 
Mild 
8 (22.2) 
26 (72.2) 
2 (5.6) 
Moderate 
28 (37.8) 
41 (55.4) 
5 (6.8) 
Severe 
8 (50.0) 
7(43.8) 
1 (6.3) 
0.308 
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Table 4.22 represents the types of renal injuries caused by diclofenac. Diclofenac was 
reported with 8 types of renal injury and the analysis demonstrates that face oedema was the 
most reported type of renal injury (n = 144; 93.5%). 
Table 4.22: Types of renal injuries caused by diclofenac reported in Malaysia 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Types of renal injury 
Creatinine blood increased 
Dysuria 
Haematuria 
Nephritis interstitial 
Nephropathy nos 
Decreased urine flow 
Acute renal failure 
Face oedema 
(N = 154) 
n 
1 
1 
1 
1 
1 
1 
4 
144 
% 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
2.6 
93.5 
4.3 Predisposing factors/predictors which susceptible to the diclofenac-induced renal 
injuries 
For the purpose of the analysis, the extent of severity were categorised into two 
categories (i.e. into non-severe and severe reaction) from the initial three groups in order to 
obtain more presentable analysis. By adjusting a model of binary logistic regression with the 
variables which include age, gender, race, dosage (in mg) and number of concomitant drugs, the 
predisposing factors or predictors which were associated with the extent of severity can be 
predicted. 
From the results, it was found that only one variable which is dosage has a significant 
association with the increase in the severity of reaction. It shows that a unit increase in dosage 
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would result in 1.017 higher odds of developing non-severe to severe reactions (95% CI: 1.007, 
1.028; P = 0.002). The rest of studied factors such as age, gender, concomitant drugs, onset of 
time and combinations of drugs with diclofenac did not show any significant association with the 
extent of severity (Table 4.23). 
Table 4.23: Factors associated with the extent of severity of diclofenac-induced renal injuries 
among the studied population 
(N = 136) 
Slogita Mlogitb 
Variables 
OR 95% CI P Adjusted 95% CI Wald P 
value OR Statistics value 
Age (years) 
Gender 
Femalec 
Male 
Race 
Malayc 
Chinese 
Indian 
Others 
Dosage (mg) 
Concomitant drug 
Drug combination 
Diclofenac alonec 
Diclofenac+other analgesics 
Diclofenac+antiHPT 
Diclofenac+others 
0.015 
-
-0.175 
-
-0.296 
0.066 
0.828 
0.017 
0.326 
-
-0.432 
0.379 
1.919 
0.995,1.036 
-
0.417,1.689 
-
0.276,2.004 
0.432,2.637 
0.469,11.165 
1.007,1.028 
0.938,2.049 
-
0.210,2.008 
0.281,7.588 
0.863,53.823 
0.144 
- -
0.623 
0.659 
0.558 
0.887 
0.306 
0.002 1.017 
0.102 
0.234 
0.453 
0.652 
0.069 
- - -
- - -
- - -
1.007,1.028 9.971 0.002 
- - -
- - -
a
 Simple Logistic Regression. Variables with p value less than are 0.25 considered into the multivariable selection 
(Age & Dosage); b Multiple Logistic Regression; c as reference; Backward LR is used in the multivariable selection; 
Multicollinearity and interaction not done as the factor (variable) selected is only one 
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CHAPTER 5 
DISCUSSION 
5.1 Roles of Spontaneous ADR Reporting 
Adverse drug reactions (ADRs) can lead to damaging effects on patients' well-being and 
to the overall health care system. A wide-range constant ADR programs in the health care system 
can help to supplement the risk management activities of an organisation, assess the safety of 
drug therapies, measure related ADR incidences, educate and increase the awareness level of the 
health care professionals regarding ADRs. Dissemination of this information to the health care 
professionals assists in promoting drug safety in organizations. Thus, periodic evaluation of 
ADR data for incidence and pattern is highly essential. 
Spontaneous adverse drug reactions monitoring and reporting programs are aimed to 
facilitate the identification and quantification of the risks associated with the use of drugs. This 
kind of retrospective study shows that spontaneous adverse reaction reporting can act as a 
beneficial tool in pharmacovigilance studies. It is notable that drugs safety profiles at the time of 
regulatory approval are often deficient due to the short duration of studies, limited sample sizes, 
limited comparison groups, narrowly defined population, narrow set of indications and lack of 
generalisability of pre-approval clinical trials (Stergachis, Hazlet, & Boudreau, 2008). The pre-
marketing conditions under which patients are studied do not fully reflect the way the product 
will be used in practice once the drug is marketed. Certain adverse effects may not be detected 
no matter how extensive the pre-clinical work in animals and the clinical trials in patients were 
carried out until a very large number of people use the product. Thus, post-marketing 
surveillance is highly needed to detect and evaluate adverse drug reactions (ADRs) of drugs 
(Ahmad, 2003). Undeniably, information obtained from pharmacovigilance activity is useful to 
aid in the decision-making process. Moreover, when adequate reporting rates and consumption 
data are available, it is possible to utilise the spontaneous reporting data to give a useful 
impression of the frequency of ADRs. The information could lead to changes such as restrictions 
in product's use, reinforcements of specific warnings and modification in dosage instructions. At 
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times, a drug may have to be withdrawn from the market when the risk is considered intolerable 
("Malaysian Guidelines for the Reporting & Monitoring," 2002) 
5.2 Drug-induced renal injuries in Malaysia 
Given the kidneys' roles in plasma filtration and maintenance of metabolic homeostasis, 
toxic effects on the kidney related to medications are both common and expected. Renal toxicity 
can be a result of direct injury to cells and tissue, inflammatory tissue injury, hemodynamic 
changes, and/or obstruction of renal excretion. Detection is often delayed until an obvious 
change in renal functional capacity is measured as there is an increase in serum blood urea 
nitrogen or creatinine or other physical changes. The true incidence of drug-induced renal injury 
is therefore difficult to determine. Most episodes of drug-induced renal failure are reversible, 
with function returning to baseline when the suspected medication is discontinued. Drugs can 
damage the kidney through dose-related toxic effects on tubular epithelial cells or on the renal 
vasculature (leading to vasoconstriction and ischemia), or through non-dose-related immunologic 
mechanisms (Perneger, Whelton, & Klag, 1994) 
This study was conducted based on the spontaneous ADR reports sent to National 
Pharmaceutical Control Bureau (NPCB), reported between January 2010 and December 2014 in 
Malaysia. An evaluation of the 5-year data was done for various parameters which included 
sources of reports, patient demographics, drugs and reaction characteristics. Analyses were also 
done for causality, extent of severity, outcome of the reactions and the predisposing factors 
related to drug-induced renal injuries caused by most common drug reported in Malaysia. 
Overall, a total of 2093 ADRs related to drug-induced renal injuries were reported to 
NPCB during the 5-year period under consideration. From the extracted data, after removal of 
possible duplications and exclusion of reports derived from literatures, a number of 1874 reports 
were considered to be analysed throughout this study. Since more than one drug might be 
implicated in a report, 2086 drugs were recorded as the suspected drugs that induced renal 
injuries (1.11 drugs per report). From the descriptive analysis, it was found that Selangor is the 
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state that sent the highest number of reports to NPCB (n = 389; 20.8%>) and this is followed by 
Kuala Lumpur (n = 207; 11%>) and Perak (n = 186; 9.9%). Wilayah Persekutuan Labuan was 
found to be the state with the lowest number of reports sent to NPCB (n = 13; 0.7%). By 
institutions, government hospitals sent the highest number of reports with a number of 1334 
reports (71.2%). NPCB received ADR reports not only from the government sector, but also 
from the private sectors. The number of reports by private sectors was led by the pharmaceutical 
companies with a total number of reports of 183 (9.8%). Almost sixty-seven percent of the 
reports (n = 1249) were sent by pharmacists, followed by the medical officers working in the 
government hospitals (n = 246, 13.1%). Pharmacists were found to be the highest number of 
reporters as the Pharmaceutical Services Division of Ministry of Health Malaysia has set a key 
performance indicator (KPI) for the pharmacists (in clinical settings) to send ADR reports at 
least one report per month. Besides that, it is most probably due to pharmacists' role in drug 
administration and close contact with both physicians and patients. 
Analysis on patients' demographics shows that female has a higher number of renal 
related ADRs (52.1%) as compared to male. Almost half of the cases reported that the patients 
were Malay (n = 927; 49.5%), followed by Chinese with 16.8% (n = 315), Indian with 12.8% (n 
= 239) and other races with 9.0% (n = 168). The mean age of patients was 42.97 (SD ± 21.49). 
Patients within 46 to 60 years old were found to be highest group of patients reported with drug-
induced renal injuries (n = 501; 24.1%). Patients who are more than 75 years old were found to 
be the least reported patients with ADRs related to drug-induced renal injury (n = 76; 4.1%). In 
India, a prospective cross sectional study by Chatterjee et al. (2015) reported that, the mean age 
of the patients with drug related renal complications was 45.3 ± 16.1 years. However, it needs 
to be pointed out that the majority of the patients present in the study were males (65.8%). 
Concluding causality assessment of the reports was made based on World Health 
Organization (WHO) causality assessment criteria. Malaysian Adverse Drug Reactions Advisory 
Committee (MADRAC) committee has made a consensus during their monthly meeting on the 
final causality of each report. Based on the causality assessment analysis, most of the reactions 
belonged to the possible category. This pattern followed by probable (10.7%) and certain (3.3%) 
cases in second and third place respectively. This pattern also similar to the results in another 
study conducted by Su et al. (2007) in Taiwan. 
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Considering the extent of the severity of reactions, almost half of the reactions were 
moderate in severity which is similar to the observations made by other comparable studies 
(Gholami & Shalviri, 1999; Su et al., 2007). The ranking of severity followed by mild reactions 
which accounted for 27.5% and only 15.2% of the reactions were deemed to be severe. 
Among the reports with concomitant drugs or polypharmacy; mild, moderate and major 
uses of multiple drugs were present in 90.6%, 6.6% and 281%> of the reports respectively. Most 
of the reports stated that the use of multiple drugs does not exceed 3 drugs. 
Many studies have shown that age, gender and number of concomitant drugs are 
significant risk factors for the development of ADRs (Bates et al., 1999; Evans, Lloyd, Stoddard, 
Neberker, & Samore, 2005; Gonzalez-Martin, Caroca, & Paris, 1998). In this study, chi-square 
tests were done to point out the association between patient related risk factors and the extent of 
severity. However, the results showed that there is no association between gender (P = 0.181), 
race (P = 0.269) and age groups (P = 0.563) with the extent of severity. The results are different 
from findings in other studies. A study by Jose and Rao (2006) had concluded that gender was 
specifically a predisposing factor only in a few (1.5%) of the adverse reaction reports while age 
(32.4%o) was a contributing factor in many of the reports, in which, geriatric group (68.2%>) being 
the major one. Furthermore, a chi-square test was also done to investigate the risk factor of 
number of concomitant drugs. The result showed that there is a strong association between 
concomitant drug groups and the extent of severity. The result of the test pointed out that the 
drug group of 0 - 3 drugs has a higher occurrence of severe type of reactions (76.1%>; P = < 
0.001). Jose and Rao (2006) also revealed that number of drugs is one of the most prevalent 
predisposing factors in patients who developed ADRs. From their observations, many reports 
were submitted from the medicine department where usually the patients have multiple co-
morbidities. Hence, polypharmacy contributed to the high percentage of reports with these 
factors as the predisposing ones in their study. 
The onsets of time to reactions were counted from the time of the first ingestion of the 
drugs until the appearance of the adverse reaction. The onset of event was categorised into three 
groups i.e. acute (less than 60 minutes), sub-acute (1 to 24 hours) and latent (more than 24 hours). 
Most of cases were reported with sub-acute reaction (n = 730; 39.0%>), followed by latent 
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reactions (n = 475; 25.3%) and acute reactions (n = 275; 14.7%). A chi square test was done to 
determine the association between onsets of time category and the extent of severity. The test 
proved that there is a strong association between onsets of time category and the extent of 
severity (P = < 0.001) where the latent onset of time has a higher occurrence of severe adverse 
reactions (41.6%). 
Frequently, drug withdrawal or dose reduction is the first step to be employed for the 
management of an ADR. In this study, in 84.4% of the reports, the suspected drug was 
withdrawn or the dose was reduced after the ADR was suspected. Out of that percentage, 67.1% 
of the patients experienced definite improvements while the rest had no improvement after 
dechallenge. No change in therapy or additional treatment (medication still continued at the time 
of reporting) was instituted in 1.9% of cases. Drug rechallenge was done only in 2.4% of reports. 
Presence of a safer alternative drug and many of the reactions being of the hypersensitivity 
nature where rechallenge is not a wise option may result in this low number. In majority of the 
reactions (66.3%), patient recovered completely without sequele, a finding which is similar to 
the findings on hospitalised patients observed by Suh et al. in their study (Suh, Woodall, Shin, & 
Hermes-De-Santis, 2000). From this study, it was also found that 13 death cases were reported in 
which may be caused by drugs or the adverse reactions. 
Overall, there were 85 types of renal injuries reported and recorded throughout this study. 
One report may have more than one type of renal injury cases. Out of 1904 cases, face oedema 
was found to be at the top of the list with more than half (n = 1157, 60.8%) of the cases reported. 
This is followed by creatinine blood increase (n = 173, 9.1%) and haematuria (n = 112, 5.9%) in 
second and third place respectively. Based on a study conducted in Taiwan, Su et al. (2007) list 
some of the most frequently reported adverse drug reactions which are acute renal failure 
(26.2%), followed by renal impairment (10.8%), renal failure (9.9%), dysuria (8.7%) and 
haematuria (8.1%). 
An analysis of common drugs causing drug-induced renal injuries reported in Malaysia 
was performed. It was found that it involved a total of 31 pharmaceutical groups or drug classes. 
From the comparison of the top 10 pharmaceutical groups from 2010 till 2014, it shows that that 
cardiovascular agents, analgesics and anti-infectives are the three groups that are always the top 
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three of the list. In total, from 2010 until 2014, it was found that analgesic is the highest drug 
class most commonly involved in the reactions of renal injuries (n = 496; 23.78%). This is 
followed by anti-infectives (n = 448; 21.48%) and cardiovascular agents (n = 380; 18.22%) in 
second and third place respectively. This finding is consistent with other studies in which 
analgesics or anti-infectives were most commonly associated with renal injuries (Dasta, 
Goldstein, Golper, & Schetz, 2010; Davidman et al., 1991). 
The collected data were further analysed for common drugs inducing renal injuries 
according to the generic names of the drugs. From the descriptive analysis, it was found that a 
total of 346 types of generics were reported and comparisons of top 10 generics were done from 
2010 until 2014. As indicated by the results, it can be observed that since 2011 till 2014, 
diclofenac has never failed to be at the top of the list as compared to the other generics as the 
number of the diclofenac-induced renal injuries has increased from year by year. Other drugs 
that were found to be on the top 3 ranking include ibuprofen, aspirin and paracetamol. The 
number of cases and the ranking of ibuprofen as one of the most common drugs that causes renal 
injuries also kept increasing from 2010 until 2014. Overall, from 2010 until 2014, still, it was 
found that diclofenac has the highest number of reports to cause renal injuries (n = 152; 7.3%) as 
compared to other generics. This is followed by ibuprofen (n = 95; 4.6%) in second place and 
aspirin or acetyl salicylic acid (n = 92; 4.4%) in third position. As in Malaysia, a report from 
New Zealand PHARMAC data (renal adverse reaction reports from 1st January 2000 to 31st 
December 2012) also documented that diclofenac was the most commonly implicated NSAID 
causing renal adverse effects in the country. As reported by Gallelli et al. (2007), diclofenac is 
the NSAIDs most frequently involved in the development of ADRs. A study in Italy that 
assessed the ADR cases based on their spontaneous ADR reporting also mentioned that several 
cases of acute renal failure in patients with risk factors for renal disorders were also reported for 
diclofenac (Conforti, Leone, Moretti, Mozzo, & Velo, 2001). 
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5.3 Analysis of the most reported drug inducing renal injuries and the predisposing factors. 
As the most common drug reported to induce renal impairment, diclofenac was further 
analysed for its pattern of adverse reactions reporting. Globally, the incidence of nephrotoxicity 
with diclofenac is around 3% (Rehan, Arora, Kumar, & Bhajoni, 2014). Diclofenac (2-[(2,6-
dichlorophenyl)amino]phenylacetate) is one of the most frequently used nonselective non-
steroidal anti-inflammatory drugs (NSAIDs) and is prescribed to millions of people worldwide 
for the treatment of osteoarthritis, rheumatoid arthritis, and muscle pain (Hickey, Raje, Reid, 
Gross, & Ray, 2001; Ng, Vincent, Halliwell, & Wong, 2006). 
A precise statistical description of the incidence of renal injuries induced by diclofenac is 
quite difficult to achieve. This is in view of the heterogeneity of the populations who consume 
these agents. However, in most general populations, approximately 1-3% of persons exposed to 
diclofenac will manifest one of several renal injuries that usually require intervention. Although 
this percentage is relatively low, the numbers of individuals who are "at risk" are very high 
because of the current use of diclofenac profile and its vast availability either by prescription or 
as an over-the-counter drug. In general, the primary diclofenac related to abnormalities of renal 
function include (i) fluid and electrolyte disturbances; (ii) acute deterioration of renal function; 
(iii) nephrotic syndrome with interstitial nephritis and (iv) papillary necrosis (Whelton & Watson, 
1991). 
Diclofenac exhibits properties of antirheumatic, antiinflammatory, analgesic and 
antipyretic. It owes its effects to the inhibition of prostaglandins from arachidonic acid by the 
enzyme cyclooxygenase (COX). Prostaglandins are omnipresent substances that influence a 
variety of body systems including renal function. They are local hormones that act in a paracrine 
or autocrine fashion. Prostaglandins are derived from phospholipids and synthesized on demand, 
not stored in tissues. Oxygenation of arachidonic acid is catalysed by COX and this is the step 
where NSAIDs carry out the inhibition. Nonselective NSAIDs, like diclofenac, inhibit both 
COX-1 (constitutively expressed in the kidney) and COX-2 (produced in most tissues in 
response to inflammation or injury, but also present in normal adult mammalian kidneys), the 
rate limiting enzymes for the production of prostaglandins. COX-1 functions mainly in the 
control of renal hemodynamics and glomerular filtration rate (GFR), while COX-2 functions 
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primarily affect salt and water excretion (Weir, 2002). Different effects on kidney functions may 
occur if either or both of these enzymes are impeded (Horl, 2010). 
In this study, the reported age of patients' that consume diclofenac was from 1 to 81 
years old. The mean age for patients with renal injuries were 38.5 years old (SD ± 17.5) and the 
group of age which used diclofenac the most was between 16 to 30 years old (32.2%). More than 
half (57.9%o) of the patient reported to have renal injuries were women and most of the patients 
in this study were Malay (57.2%). A study by Whelton, Lefkowith, West and Verburg (2006) 
also found that most patients that used diclofenac were females but their average age of the 
patients was 60 years old. The greater consumption of medications by women may at least 
partially account for the excess of reports in the female population. 
Based on the causality assessments of the reports, it was found that most of the reactions 
were classified as possible with 71.7%, of the reports. More than half of the cases were reported 
as moderate for diclofenac (n = 85; 55.9%). According to Whelton and Watson (1991), NSAID-
induced renal impairment is basically of moderate severity. This form of drug-induced renal 
failure is usually reversible over 2-7 days upon discontinuation of therapy (Whelton & Watson, 
1991). 
According to the analyses of outcome of the ADRs, it can be onserved that most patients 
experienced a definite improvement after the dechallenge (omission or decrease in dose) of the 
suspected drugs. Most of the literature have documented that the withdrawal of NSAIDs treatment 
(including diclofenac) should usually be sufficient to improve renal function (Ashley, n.d.; Dhavinjay, 
Misra, & Varma, 2013; Whelton & Watson, 1991). In a study by Schneider, Levesque, Zhang, 
Hutchinson and Brophy (2006), they concluded that after at least 30 days without a NSAID treatment, 
the risk of renal failure returned to baseline. In this study, only a few patients did not get any 
improvement after the dechallenge where 15.8% cases had no improvement. Besides that, it also 
can be observed that no rechallenge activity was performed in almost all cases reported for 
diclofenac (96.7%). In the final outcome, about three-quarter of the patients had recovered 
without sequele from the adverse reactions. 
According to the onset of reaction time, most of cases were reported with sub-acute 
reaction (48.7%), followed by acute reactions (30.3%) and latent reactions (5.3%). This means 
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that, most of the cases reported happened between 1 to 24 hours after the ingestion of the 
suspected drug. A study carried out by Krause, Cleper, Eisenstein, and Davidovits (2005) 
indicated differently. They observed that the time interval between NSAID administration 
(including diclofenac) and the appearance of the symptoms ranged from 1 to 4 days in their study 
population (Krause et al., 2005). This means that the appearances of renal injuries observed by 
them are of latent type of reactions. A chi square test was also done to relate the association 
between the onsets of time and the extent of severity. However, the result shows no significant 
association between the two variables (P = 0.308). 
Furthermore, from this study, diclofenac was also reported with 8 types of urinary system 
disorders and the results also demonstrate that face oedema was the most reported type (93.5%). 
This is followed by acute renal failure (2.6%) and decreased urine flow (0.6%). In a study by 
Whereas Su et al. (2007) reported that the highest reported adverse drug reactions observed from 
their study were acute renal failure (26.2%), followed by renal impairment (10.8%), renal failure 
(9.9%>), dysuria (8.7%>) and haematuria (8.1%>). A previous study was conducted to compare the 
safety profile of celecoxib and nonselective NSAIDs, named CLASS-study, found that oedema, 
hypertension, and increased creatinine levels occurred more often in diclofenac than in the 
celecoxib group (Schneider, 2005) 
As stated in WHO Adverse Reaction Terminology (2012), according to the system organ 
class (SOC), face oedema has been listed under urinary system disorders with a code of SOC2 
1810 and it is often referred as a symptom of nephrotic syndromes ("Nephrotic Syndrome in 
Adults," 2012). Edema occurs in approximately 3% to 5% of patients receiving traditional 
NSAIDs. Sodium chloride and water retention are among the most commonly encountered side 
effects of the use of NSAIDs. As described briefly by Whelton (1999), NSAIDs can interfere 
with prostaglandins-mediated mechanisms, decrease sodium transport causing increased sodium 
chloride absorption. In addition, NSAIDs can interfere with the prostaglandin-mediated 
antagonism of antidiuretic hormone release. These two physiological events can directly 
contribute to sodium and water retention, edema, and diuretic resistance (Whelton, 1999). Since 
it represents a modification of a physiologic control mechanism without the production of a true 
kidney functional disorder, this may not be considered as a "toxicity" of the drug. In many adults, 
the formation of detectable edema, related to NSAID use in the absence of obvious renal 
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functional impairment, is typically seen in less than 5% of such individuals. NSAIDs induced 
fluid and the electrolyte retention is typically benign, rapidly responds to discontinuation of the 
drug, and is easily managed in those who require continuous NSAID therapy (Whelton & 
Watson, 1991). 
For the purpose of analyses of this study, from three original categories, the extents of 
severity were collapsed into two categories (i.e. into non-severe and severe reaction). By 
adjusting a model of binary logistic regression with the variables age, gender, race, dosage (in 
mg), number of concomitant drugs and the combination of drug class with diclofenac, the 
predisposing factors or predictors which were associated with the extent of severity can be 
predicted. From the result of binary logistic regression, it was found that only one variable which 
is dosage that has a significant association with the increase in the severity of reactions. The 
result shows that the increase in a unit of dosage would result in a 1.017 higher odds of 
developing non-severe to severe reactions (95% CI: 1.007, 1.028; P = 0.002). Day and Graham 
(2013) also discovered that the quantity of administered dose decides the severity of renal 
complications. In a review, Nderitu et al. (2013) reported that renal failure progression may 
result from the use of high dose NSAIDs including diclofenac. Contrarily, the rest of the studied 
factors such as age, gender, concomitant drugs and drugs combination with diclofenac did not 
show any significant association with the extent of severity. 
Although age and number of concomitant drugs (polypharmacy) do not seem to be 
significant predictors in this study, many studies have related these two variables with the extent 
of severity of renal injury. In one case-controlled study, the researchers found that not only the 
risk of renal injury increases with higher diclofenac dose, but also at age that is greater than 65 
years, and concomitant use of other nephrotoxic drugs (Gutthann, Rodriguez, Raiford, & et al, 
1996). Dhavinjay, Misra and Varma (2013) stated that elderly patients are at an increased risk of 
contracting renal complications with the use of diclofenac as renal dysfunctions are more 
prominent in geriatric population with falling renal functions. Whelton and Watson (1991) 
estimated that, in the absence of other disease entities, the age of 80 years or greater is an 
independent risk factor since the physiology of aging within the kidney will results in a 50% loss 
of glomerular function. Blatt and Liebman (2013) reported that nephrotoxicity has a possible 
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dependence on peak drug concentrations; duration of usage; frequency of dosing; route, rate, and 
timing of administration; or concomitant use of other nephrotoxins. 
The concomitant use or use of diclofenac combined with other drugs is another 
predisposing factor that is commonly discussed in much literature. Nevertheless, it is found that 
there is no significant association with the extent of severity in this study. The most commonly 
reviewed is the combination of diclofenac with antihypertensive drugs. An increase in blood 
pressure in hypertensive patients may occur due to an interaction between NSAIDs and 
antihypertensive drugs. This has been documented for the beta blocker agents, the calcium 
antagonist drugs, the ACE inhibitors (ACEIs), the angiotensin receptor blockers (ARBs) and 
diuretics. Therefore, from a clinical viewpoint, one can expect that an otherwise stable patient on 
a given antihypertensive regimen may experience some increase in blood pressure as a result of 
the addition of an NSAID to their management. NSAIDs may further increase blood pressure, 
cause fluid retention, and worsen kidney functions. In general, it is not difficult to manage this 
drug-drug-disease interaction. It must be noted that these patients may require appropriate 
dosing modification in their antihypertensive regimen (Ganguli & Prakash, 2003b; Whelton & 
Watson, 1991). In one cross-sectional study of 301 patients, the researchers found that, in 
comparison with non-use, the use of two or more drugs between diuretics, ACEIs, and 
angiotensin receptor blockers (ARBs) with NSAIDs was associated with an increased risk of 
renal impairment (Lapi, Azoulay, Yin, Nessim, & Suissa, 2013). Combinations of ACEIs or 
ARBs, diuretics and NSAIDs may impair renal function, especially among the elderly (Thomas, 
2000). In this study, there are 5 cases of combinations of diclofenac with ACEIs which resulted 
in 1 mild case, 3 moderate cases and 1 severe case. These cases involve patients from 44 to 81 
years old. It can be concluded that age affects the extent of severity as their renal functions 
deteriorate. Nonetheless, all the patients showed improvement after diclofenac was omitted. 
There is also a case where a 54 years old patient developed severe renal injury when his 
antihypertensive regimen (hydrochlorothiazide) was added with diclofenac. It is known that 
COX inhibition by diclofenac reduces the hydrochlorothiazide-induced urinary sodium excretion 
significantly and may impair the renal function (Knauf, Bailey, Hasenfuss, & Mutschler, 2006). 
However, the duration of usage of the combination was not recorded. Fortunately, the 
complication was reversible as the therapy with diclofenac was discontinued. The patient 
experienced a definite improvement after diclofenac was withdrawn. In 1992, Seelig et al had 
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performed a record search of 2278 patients with NSAIDs, 328 with ACEIs, and 162 with both. 
They claimed that no nephrotoxicity was found in conjunction with monotherapy but three cases 
of reversible ARF were observed in conjunction with the combination of NSAIDs and ACEIs. 
Therefore, detailed care is necessary to balance the demonstrated advantages of these 
medications against the risk of inducing kidney failure. 
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CHAPTER 6 
CONCLUSION, LIMITATIONS & FUTURE RECOMMENDATIONS 
6.1 Limitations of the Study 
Signal generation and identification of new ADRs are some the strengths of spontaneous 
reporting system. To date, some studies that compare the safety of different drugs based on 
spontaneous ADR reporting data have been published. Spontaneous reporting is generally 
considered as a source of signals and its success depends on the reporting rate and on the quality 
of reports (Conforti et al., 2001). However, this study has several limitations. The first limitation 
is underreporting. It is a well-known limitation of spontaneous reporting program that needs to 
be taken into consideration when interpreting the data. Furthermore, potential confounding 
factors and bias in reporting should be addressed and the spontaneous reporting data have to be 
validated by other suitable studies. In some reports, the involvement of a drug is doubtful and 
further evidence is needed in order to confirm the causality relationship between drug and the 
adverse reactions. The dissimilarities of certain results in this study can be contributed to the 
different settings of the studies and the number of samples which is considerably low for the 
specific drug, i.e. diclofenac. Since the study data was obtained from our national database, the 
conclusive results can be generalised to the entire population. The data from this study also acts 
as the preliminary study and provides an insight (especially to the healthcare professionals) on 
the pattern of ADRs related to renal injuries, which do occur and reported in Malaysia with a 
comparable pattern of patients' demographics. 
6.2 Recommendations and Conclusions 
In conclusion, this study has shown the pattern of drug-induced renal failure and urinary 
system disorders reported in Malaysia. Furthermore, this study has also pointed out diclofenac as 
the most common drug that causes renal injury aside from demonstrating the trend of renal 
injuries due to the use of diclofenac. Although diclofenac can be considered as safe and effective 
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therapeutic NSAIDs for the management of a variety acute and chronic conditions, it has to be 
used with justifiable cautions. The risk of inducing degeneration of renal function after the 
initiation of diclofenac is low. However, the number of at-risk patients is high because of the 
extensive use of it. Similarly, the risk of activating other renal syndromes, for instance the 
nephrotic syndrome, is uncommon. But, in view of the massive number of individuals who 
consume diclofenac, the development of this related syndrome must constantly be monitored. 
Based on the obtained results and comparison with related literature, some preventive measures 
can be employed. Related predisposing factors have been identified and discussed. It is prudent 
to avoid high-dose of diclofenac and it should be used with caution especially in elderly patients 
and in patients that are consuming other drugs at the time especially antihypertensive agents. As 
advised by The American Geriatric Society (AGS), the use of NSAIDs should be avoided in 
patients with abnormal renal function. Furthermore, patients who are at-risk of developing renal 
impairment should not use more than one NSAID at a time (Rose, 1998). Healthcare 
professionals should have a high awareness of the risks for diclofenac associated renal injuries 
and need to screen patients appropriately for impairment risk factors before starting diclofenac 
therapy. 
In order to obtained more significant and conclusive results, further study with prolonged 
period of time is encouraged to be conducted as more cases (samples) can be attained thus 
providing a more holistic analysis. . Besides that, a prospective study with the focus in capturing 
the patients' lab results would present a more reliable, credible and accurate in explaining the 
association of the renal injuries and the extent of severity. 
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